Next Article in Journal
Pitavastatin Ameliorates Lipopolysaccharide-Induced Blood-Brain Barrier Dysfunction
Next Article in Special Issue
High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad and the Future
Previous Article in Journal
Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
Previous Article in Special Issue
Familial Hypercholesterolemia: Do HDL Play a Role?
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important?

by
Knut Tore Lappegård
1,2,*,
Christian Abendstein Kjellmo
3 and
Anders Hovland
1,2
1
Department of Medicine, Nordland Hospital, 8092 Bodø, Norway
2
Department of Clinical Medicine, UiT The Arctic University of Norway, 9037 Tromsø, Norway
3
Department of Gastroenterology, St. Olavs University Hospital, 7030 Trondheim, Norway
*
Author to whom correspondence should be addressed.
Biomedicines 2021, 9(7), 836; https://doi.org/10.3390/biomedicines9070836
Submission received: 13 May 2021 / Revised: 24 June 2021 / Accepted: 15 July 2021 / Published: 18 July 2021

Abstract

High-density lipoproteins (HDL) are a heterogenous group of plasma molecules with a large variety in composition. There is a wide specter in lipid content and the number of different proteins that has been associated with HDL is approaching 100. Given this heterogeneity and the fact that the total amount of HDL is inversely related to the risk of coronary heart disease (CHD), there has been increasing interest in the function of specific HDL subgroups and in what way measuring and quantifying these subgroups could be of clinical importance in determining individual CHD risk. If certain subgroups appear to be more protective than others, it may also in the future be possible to pharmacologically increase beneficial and decrease harmful subgroups in order to reduce CHD risk. In this review we give a short historical perspective, summarize some of the recent clinical findings regarding HDL subclassifications and discuss why such classification may or may not be of clinical relevance.
Keywords: high density lipoproteins; HDL; HDL-C; subclasses; subfractions high density lipoproteins; HDL; HDL-C; subclasses; subfractions

Share and Cite

MDPI and ACS Style

Lappegård, K.T.; Kjellmo, C.A.; Hovland, A. High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important? Biomedicines 2021, 9, 836. https://doi.org/10.3390/biomedicines9070836

AMA Style

Lappegård KT, Kjellmo CA, Hovland A. High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important? Biomedicines. 2021; 9(7):836. https://doi.org/10.3390/biomedicines9070836

Chicago/Turabian Style

Lappegård, Knut Tore, Christian Abendstein Kjellmo, and Anders Hovland. 2021. "High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important?" Biomedicines 9, no. 7: 836. https://doi.org/10.3390/biomedicines9070836

APA Style

Lappegård, K. T., Kjellmo, C. A., & Hovland, A. (2021). High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important? Biomedicines, 9(7), 836. https://doi.org/10.3390/biomedicines9070836

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop